Recursion Pharmaceuticals, Inc. (RXRX)

Market Cap	2.46B
Revenue (ttm)	43.69M
Net Income (ttm)	-715.54M
Shares Out	521.26M
EPS (ttm)	-1.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,124,360
Open	4.870
Previous Close	4.920
Day's Range	4.670 - 4.880
52-Week Range	3.790 - 12.360
Beta	0.94
Analysts	Buy
Price Target	7.25 (+53.93%)
Earnings Date	Nov 5, 2025

About RXRX

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to trea...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 16, 2021
• Employees: 800
• Stock Exchange: NASDAQ
• Ticker Symbol: RXRX
• Website: https://www.recursion.com

Financial Performance

In 2024, Recursion Pharmaceuticals's revenue was $58.84 million, an increase of 32.00% compared to the previous year's $44.58 million. Losses were -$463.66 million, 41.3% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price target is $7.25, which is an increase of 53.93% from the latest price.

Price Target

$7.25

(53.93% upside)

Analyst Consensus: Buy